The Egyptian Journal of Haematology

ORIGINAL ARTICLE
Year
: 2012  |  Volume : 37  |  Issue : 2  |  Page : 96--101

Cost-effectiveness of postremission intensive chemotherapy in comparison with allogeneic stem-cell transplantation in adult Egyptian patients with acute myeloid leukemia


Essam A Hassan, Amal M El Afifi, Nermeen Adel Nabih, Walaa Ali ELSalakawy 
 Internal Medicine Department, Hematology and Bone Marrow Transplant Units, Ain Shams University, Cairo, Egypt

Correspondence Address:
Walaa Ali ELSalakawy
16 abdellatif elfaham St. Menniat Elsereg, Alkhalaphawy, Shoubra, Cairo
Egypt

Background

We assessed the cost-effectiveness of postremission high-dose arabinoside (HiDAC)-based chemotherapy in comparison with allogeneic stem-cell transplantation (alloSCT)-based therapy in adult Egyptian patients with acute myeloid leukemia at either an intermediate or a poor cytogenetic risk.

Patients and methods

Forty young patients at either an intermediate or a poor cytogenetic risk received postremission intensive therapy (20 HiDAC-based/20 alloSCT-based). We analyzed the overall survival, disease-free survival, and cost effectiveness in both groups.

Results

Patients were followed up over a period of 60 months. The mean overall survival was 36.32 months for the HiDAC-based group, whereas it was 48.8 months in the alloSCT-based group. The mean disease-free survival was 24.8 months in the HiDAC-based group, whereas it was 51.5 months in the alloSCT-based group. The mean total cost in the HiDAC-based group was 51 300 Egyptian pounds (nearly US$9000), whereas it was 88 250 Egyptian pounds (nearly US$15 482) in the alloSCT-based group.

Conclusion

For the postremission therapy in young acute myeloid leukemia patients at either an intermediate or a poor cytogenetic risk, HiDAC-based chemotherapy is less costly and less effective, whereas alloSCT is more costly and more effective in maintaining patients in durable remission.




How to cite this article:
Hassan EA, El Afifi AM, Nabih NA, ELSalakawy WA. Cost-effectiveness of postremission intensive chemotherapy in comparison with allogeneic stem-cell transplantation in adult Egyptian patients with acute myeloid leukemia.Egypt J Haematol 2012;37:96-101


How to cite this URL:
Hassan EA, El Afifi AM, Nabih NA, ELSalakawy WA. Cost-effectiveness of postremission intensive chemotherapy in comparison with allogeneic stem-cell transplantation in adult Egyptian patients with acute myeloid leukemia. Egypt J Haematol [serial online] 2012 [cited 2019 Dec 12 ];37:96-101
Available from: http://www.ehj.eg.net/article.asp?issn=1110-1067;year=2012;volume=37;issue=2;spage=96;epage=101;aulast=Hassan;type=0